|
KR102709603B1
(ko)
|
2017-02-28 |
2024-09-27 |
보르 바이오파마 인크. |
계통 특이적 단백질의 억제를 위한 조성물 및 방법
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
AU2020216484A1
(en)
*
|
2019-01-31 |
2021-07-29 |
Beam Therapeutics Inc. |
Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
US10913941B2
(en)
|
2019-02-14 |
2021-02-09 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2021046243A2
(en)
*
|
2019-09-03 |
2021-03-11 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
EP4204564A1
(en)
*
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
|
EP4211245A1
(en)
*
|
2020-09-14 |
2023-07-19 |
Vor Biopharma Inc. |
Compositions and methods for cd5 modification
|
|
WO2022061115A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
|
KR20230074515A
(ko)
*
|
2020-09-23 |
2023-05-30 |
크리스퍼 테라퓨틱스 아게 |
개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
|
|
AU2021347359A1
(en)
*
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
WO2022072643A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Vor Biopharma Inc. |
Compositions and methods for cd30 gene modification
|
|
CN116801890A
(zh)
*
|
2020-11-04 |
2023-09-22 |
小利兰·斯坦福大学董事会 |
用于增强治疗性免疫细胞功效的方法和组合物
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
EP4255453A4
(en)
*
|
2020-12-03 |
2025-03-26 |
Nkarta, Inc. |
Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
|
|
EP4259792A1
(en)
*
|
2020-12-11 |
2023-10-18 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
MX2023008809A
(es)
|
2021-01-29 |
2023-08-04 |
Allogene Therapeutics Inc |
ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
|
|
WO2022215978A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
|
|
CN113179160B
(zh)
*
|
2021-04-15 |
2022-03-18 |
中国电子科技集团公司第三十研究所 |
一种适用于qkd中私钥放大的最优输入码长处理方法及单元
|
|
CA3217459A1
(en)
*
|
2021-05-06 |
2022-11-10 |
Spyro Mousses |
Compositions for inhibiting growth of targeted cells
|
|
WO2022241029A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
EP4388105A4
(en)
*
|
2021-08-16 |
2026-02-11 |
Beam Therapeutics Inc |
Persistent Allogeneic Modified Immune Cells and Their Methods of Use
|
|
CN119452085A
(zh)
|
2021-08-27 |
2025-02-14 |
宏基因组学公司 |
具有ruvc结构域的酶
|
|
US20250134998A1
(en)
*
|
2021-08-30 |
2025-05-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
T cells with cell-surface expression of adenosine deaminase and uses thereof
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
CN113980896B
(zh)
*
|
2021-10-27 |
2023-10-20 |
中国人民解放军军事科学院军事医学研究院 |
Irf1在调控间充质干细胞免疫调节作用及产品上的应用
|
|
WO2023081200A2
(en)
*
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
EP4430195A4
(en)
*
|
2021-11-12 |
2025-09-24 |
Georgia Tech Res Inst |
ADENOSINE DEAMINASE 1 COMPOSITIONS AND METHODS OF USE THEREOF
|
|
KR20240110603A
(ko)
|
2021-11-24 |
2024-07-15 |
메타지노미, 인크. |
엔도뉴클레아제 시스템
|
|
CA3242360A1
(en)
*
|
2021-12-10 |
2023-06-15 |
Beam Therapeutics Inc. |
Modified immune cells and methods of using the same
|
|
WO2023114777A2
(en)
*
|
2021-12-14 |
2023-06-22 |
The Trustees Of The University Of Pennsylvania |
Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors
|
|
CN114774364B
(zh)
*
|
2022-04-26 |
2024-04-26 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
EP4532697A2
(en)
*
|
2022-06-03 |
2025-04-09 |
Beam Therapeutics Inc. |
Modified regulatory t cells and methods of using the same
|
|
WO2024026284A2
(en)
*
|
2022-07-25 |
2024-02-01 |
Interius Biotherapeutics, Inc. |
Mutated polypeptides, compositions comprising the same, and uses thereof
|
|
KR20240035722A
(ko)
*
|
2022-09-08 |
2024-03-18 |
주식회사 에이조스바이오 |
세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
|
|
JP2025532585A
(ja)
*
|
2022-09-16 |
2025-10-01 |
アーセナル バイオサイエンシズ インコーポレイテッド |
組み合わせ遺伝子摂動を有する免疫細胞
|
|
JP2025531268A
(ja)
*
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
KR20250084940A
(ko)
*
|
2022-09-30 |
2025-06-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
입양 t 세포 치료를 향상시키기 위한 조성물 및 방법
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
WO2024186841A2
(en)
*
|
2023-03-06 |
2024-09-12 |
La Jolla Institute For Immunology |
Nfkbid cells and methods for immunotherapy
|
|
CN121358848A
(zh)
*
|
2023-03-21 |
2026-01-16 |
苏州沙砾生物科技有限公司 |
一种修饰的细胞及其用途
|
|
EP4694917A1
(en)
*
|
2023-04-12 |
2026-02-18 |
Beam Therapeutics Inc. |
Modified immune effector cells with improved efficacy
|
|
EP4455157A1
(en)
*
|
2023-04-27 |
2024-10-30 |
Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps |
Polynuceotide for t cell specific transgene expression
|
|
CN121532511A
(zh)
*
|
2023-05-16 |
2026-02-13 |
先导药物有限公司 |
靶向b2m基因的基因组编辑组合物及使用方法
|
|
WO2024249346A1
(en)
*
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting cd70 expression
|
|
CN116590237B
(zh)
*
|
2023-05-29 |
2023-10-31 |
上海贝斯昂科生物科技有限公司 |
一种遗传修饰的自然杀伤细胞及其制备和用途
|
|
WO2025111533A1
(en)
*
|
2023-11-22 |
2025-05-30 |
The General Hospital Corporation |
Car-t cells comprising a cdkn1b gene knockout and methods of use thereof
|
|
CN122349566A
(zh)
*
|
2023-12-06 |
2026-07-07 |
北京齐禾生科生物科技有限公司 |
优化的qbe碱基编辑系统及其应用
|
|
WO2025122896A1
(en)
*
|
2023-12-08 |
2025-06-12 |
The Trustees Of The University Of Pennsylvania |
Cd5 modified cells comprising heterologous tcrs and methods of using the same
|
|
IT202400011104A1
(it)
*
|
2024-05-16 |
2025-11-16 |
Fondazione St Italiano Tecnologia |
Progettazione di mirna sintetici per ristabilire il corretto dosaggio genico dei geni associati all'esaurimento dei linfociti t
|
|
KR102955030B1
(ko)
*
|
2025-11-04 |
2026-04-23 |
대한민국 |
신규한 가이드 rna 및 이의 용도
|